⇐ All news
Praluent (alirocumab) reduces mortality for atherosclerotic cardiovascular diseases (ASCVD)
Praluent is the only PCSK9- inhibitor approved in EU. The collected data indicate a mortality decrease in cardiovascular diseases.
Optimizer Smart – breakthrough device for the treatment of cardiac insufficiency
On March 21, 2019, the FDA approved an innovative device – Smart Optimizer System for treating patients with moderate to severe chronic cardiac insufficiency (CHF) with CCM technology.